Tod O. White is a founding partner of EMA Partners, LLC. During his tenure at EMA, Mr. White has advised clients on numerous transactions, primarily in the technology, life sciences and healthcare spaces.

Prior to founding EMA, Mr. White was General Counsel, Vice President and Secretary of Packard BioScience Company, where he was responsible for negotiating numerous acquisitions, divestitures, license agreements and financing deals. In addition, Mr. White oversaw the company's initial public offering (IPO) in 2000, and ultimately the merger of the company with PerkinElmer, Inc.

Prior to joining Packard, Mr. White was a transactional attorney at the Denver law firm of Jacobs, Chase, Frick, Kleinkopf & Kelley, LLC, where his practice included mergers, acquisitions, financings and securities work. Prior to that, Mr. White was a transactional attorney in the Denver office of Ballard, Spahr, Andrews & Ingersoll.

Mr. White holds a Bachelor of Arts degree from Hamilton College and his law degree from The University of Michigan Law School, where he graduated with honors. Mr. White holds FINRA Series 79, Series 63, and Series 62 license.

Andrew D. Raeder is a founding partner of EMA Partners, LLC. For over 20 years, Mr. Raeder has advised middle market clients on numerous transactions in a variety of industries, from life sciences and medical devices, to specialty manufacturing, healthcare IT, and consumer products. Prior to co-founding EMA, Mr. Raeder was a founding partner of The Suffield Financial Group, LLC. During his tenure at SFG, and at Delta Capital Group, Mr. Raeder specialized in lower middle market merger and acquisition work.

For almost ten years, Mr. Raeder worked as a consultant to, and ultimately the President and CEO of two privately held companies: one in the consumer products industry, and the other a manufacturer of medical devices. He ultimately prepared and sold each company to larger competitors in their respective industries. Prior to that, Mr. Raeder worked as a business development consultant and financial analyst for several successful entrepreneurs, including the founders of the WD-40, Foto-Mat, and Smart Food companies. Mr. Raeder also performed due diligence support for mergers and acquisitions at Kirkland and Ellis, LLP. He worked on some of the largest transactions of the period, including Kraft Foods/Philip Morris, and Whirlpool/Roper. Other clients included Celestial Seasonings and Motorola Corporation.

Mr. Raeder graduated from Princeton University with a Bachelor of Arts in English, and holds an MBA from The University of Michigan. Mr. Raeder holds FINRA Series 79, Series 63 and Series 62 licenses.


David Esposito is a seasoned healthcare executive and combat veteran who has built and scaled multiple healthcare companies resulting in successful exits to strategic buyers. Most recently, Mr. Esposito served as CEO of Armune BioScience, an early commercial stage, cancer diagnostics company. After the successful introduction of the only cancer specific, non-PSA blood test available in the world to assess the risk of prostate cancer, growing demand to over 15,000 tests, and making progress on a pipeline of products, Armune gained the interest of numerous strategic buyers and closed a deal with Exact Sciences in December of 2017 to acquire core assets of the business.

Prior to leading Armune, Mr. Esposito served as President of Phadia US Inc. (Phadia US, was the US division of privately held, Phadia AB, a premier global specialty diagnostics company). He led several initiatives to accelerate top and bottom line growth which culminated in the sale to Thermo Fisher Scientific for $3.5B USD in 2011.

Before joining Phadia, Mr. Esposito spent 16 years at Merck & Co., Inc. After starting his career as a sales representative, he progressed through key leadership roles in sales, marketing and commercial strategy.

Mr. Esposito has a B.S. in Civil Engineering from the United States Military Academy at West Point and an MBA from Syracuse University.

Prior to joining EMA, Mr. Kwiat held executive positions with Hewlett-Packard that included outsourcing operations management, account management, and management consulting. Over an 18 year tenure, he led teams that serviced Fortune 100 clients within the Information Technology, Telecommunications, Consumer Packaged Goods, and Life Sciences industries.

Before joining HP, Mr. Kwiat was in the Medical Diagnostics industry as the Manager of New Product Development and Product Manager at Siemens Medical systems. These business development roles were capstones of a decade of software and systems engineering while at Siemens, Computer Technology & Imaging, and GE Medical Systems, bridging across the CT, MR, PET, Nuclear Medicine and PACS modalities.

Mr. Kwiat holds an MBA from The University of Colorado Executive program, and a B.S. in Computer and Communication Sciences from The University of Michigan

Ms. Stump has more than 25 years of corporate financial planning and analysis experience in the biotechnology and food industries, which included various roles related to mergers and acquisitions. Prior to joining EMA, she served as an Associate Director of Finance for Amgen Corporation, where she supported the Research and Preclinical organization by providing valuation expertise for licensing and acquisition opportunities. Prior to Amgen, Ms. Stump was a Director of Financial Planning and Analysis for Immunex Corporation, a biotechnology company subsequently acquired by Amgen, for which she developed the valuation models to support the deal and was a key partner in the merger process. She began her career as a financial analyst working for Nalley's Fine Foods and participated in a number of divestiture and licensing agreements.

Ms. Stump holds an MBA from Pacific Lutheran University Graduate School of Business and a BA in Finance and International Business from the Honors College of Washington State University. Ms. Stump holds a FINRA Series 79 license.

Ms. Schrader’s background is in running companies and business divisions for nearly 20 years, with a focus in the life science sector for the last 10 years. Prior to joining the EMA team, she was President and CEO of the preclinical laboratory product company 3D Biomatrix, Inc. Before this she served as a senior business consultant for a medical device consulting firm for many years, after selling her own company in the retail sector.

Early in her career Ms. Schrader worked in economic development at the regional, state and national levels where she facilitated technology spinout collaborations between the U.S. government and the private sector and managed a federally-funded revolving loan fund. She holds a BA in business and economics from Olivet College and a product development certification from the University of Chicago Booth School of Business. She played college varsity basketball and was inducted into the Collegiate Athletic Hall of Fame.

Christopher B. Anderson has been associated with EMA Partners since 2003. In addition, Mr. Anderson has been a Managing Director for Blue Sage Advisors, Allied Business Group (a division of Mariner Wealth Advisors) and most recently The Scott Company/TSC Advisors.  Mr. Anderson began his M&A Investment Banking career at W.G.Nielson & Co. over 15 years ago, during which he has advised middle market clients on numerous transactions in a variety of industries, from consumer products (especially food and beverage), to energy services, distribution, specialty manufacturing, and business service clients.

Mr. Anderson holds a LL.M in Taxation from The University of Denver School of Law, a J.D. from California Western School of Law, and a B.A from The University of Michigan. Mr. Anderson holds FINRA Series 79 and Series 63 licenses.

David Olson is a serial entrepreneur who has co-founded six biotech start-ups, managed early-stage businesses, and authored business plans that generated substantial private and public funding.  Dr. Olson specializes in commercializing early stage life science technologies and has more than 20 years of experience in building life science companies, product development, intellectual property management, business development and venture financing.  Dr. Olson is currently a Mentor-in-Residence and Adjunct Faculty at the University of Michigan.  Previously he was CEO and co-founder of Swift Biosciences Inc. where he led the creation, funding and development of the company for six years.  During that time Swift invented and brought to market multiple new technologies for genetic analysis and Next Generation Sequencing.  Prior to Swift Biosciences, Dr. Olson was a founding member and senior executive of Accuri Cytometers (acquired by Becton Dickinson), which developed a successful product line of flow cytometers.  His other companies have focused on therapeutics and medical devices.  Dr. Olson received his PhD in Molecular Biology from Princeton University and completed a postdoctoral fellowship at the University of California, San Francisco.

Mr. Goodman has more than 20 years of strategy, marketing, e-commerce and operations experience in the retail sector. He served as EVP and Chief Marketing Officer-Strategy, Membership and E-Commerce for Wal Mart/Sam's Club. Prior to Sam's Club, Mr. Goodman was Corporate Vice President, US Strategy and Operations for McDonald's Corporation. Mr. Goodman served as Chief Restructuring officer and CEO for a Goldman Sachs Private Equity retail company, was COO of the Save-A-Lot chain of 1200 stores, served as President of Agway Retail Services, and was Vice President of ADR International Consultants.

Early in his career, Mr. Goodman served as an economic and foreign policy advisor to Senator Edward Kennedy. Mr. Goodman sits on the Board of Directors of the St. Louis University School of Business and Livingstone College. He also sits on the Board of Directors of The HistoryMakers.

Mr. Goodman holds a Bachelor's degree in Philosophy of Economics and Logic from The College of Wooster, and Masters degrees in both Economics and Philosophy from Tufts University.

Ms. Webster's background is primarily in consumer products. Prior to joining EMA, Ms. Webster was a Marketing Manager for International Distillers & Vintners (now Diageo), working on several wine and spirits brands, including Glen Ellen Proprietor's Reserve, Black Velvet Canadian Whisky, and Almaden Vineyards. Prior to IDV, Ms. Webster was in accounting, administering 401 (k) plans for Manufacturers National Bank of Detroit.

At EMA, Ms. Webster focuses on research and outreach, and has worked extensively with clients in healthcare, business services, Federal IT, consumer products, manufacturing, software, and construction services.

Ms. Webster holds a BA in Finance from Michigan State University, and an MBA in Marketing and General Management from The University of Michigan. Ms. Webster holds FINRA Series 79 and Series 63 licenses.